Nurgül Örnek1, Kemal Örnek1, Süleyman Aydin2, Musa Yilmaz2, Yaşar Ölmez1. 1. Department of Ophthalmology, School of Medicine, Kirikkale University, Kirikkale 71450, Turkey. 2. Department of Biochemistry, School of Medicine, Firat University, Elazig 23300, Turkey.
Abstract
AIM: To investigate the serum levels of vascular endothelial growth factor receptor-2 (VEGFR-2) and adropin in age-related macular degeneration (AMD) patients. METHODS: Ninety-eight AMD patients were included in the study. Seventy-eight age- and sex-matched healthy volunteers were recruited as the control group. Fundus florescein angiography and optical coherence tomography were performed to assess the posterior segment details. Serum VEGFR-2 and adropin levels were measured using enzyme-linked immunosorbent assays and compared between the study groups. RESULTS: AMD group had significantly increased foveal retinal thickness, serum LDL and HDL levels and significantly decreased subfoveal choroidal thickness (P =0.01, 0.047, 0.025 and <0.001, respectively). Serum VEGFR-2 level revealed a significant decrease in AMD patients compared to controls (26.48±6.44 vs 30.42±7.92 ng/mL, P<0.001). There was an insignificant increase in serum adropin level in AMD patients (6.17±3.19 vs 5.79±2.71 ng/mL, P=0.4). Serum level of VEGFR-2 in AMD patients had a significant negative correlation with foveal retinal thickness (r=-0.226, P=0.025) and a significant positive correlation with subfoveal choroidal thickness (r=0.2, P=0.048). CONCLUSION: The current study demonstrated that the decreased serum VEGFR-2 level may be considered in the development of AMD. Adropin does not seem to play a role in the pathogenesis of AMD.
AIM: To investigate the serum levels of vascular endothelial growth factor receptor-2 (VEGFR-2) and adropin in age-related macular degeneration (AMD) patients. METHODS: Ninety-eight AMDpatients were included in the study. Seventy-eight age- and sex-matched healthy volunteers were recruited as the control group. Fundus florescein angiography and optical coherence tomography were performed to assess the posterior segment details. Serum VEGFR-2 and adropin levels were measured using enzyme-linked immunosorbent assays and compared between the study groups. RESULTS:AMD group had significantly increased foveal retinal thickness, serum LDL and HDL levels and significantly decreased subfoveal choroidal thickness (P =0.01, 0.047, 0.025 and <0.001, respectively). Serum VEGFR-2 level revealed a significant decrease in AMDpatients compared to controls (26.48±6.44 vs 30.42±7.92 ng/mL, P<0.001). There was an insignificant increase in serum adropin level in AMDpatients (6.17±3.19 vs 5.79±2.71 ng/mL, P=0.4). Serum level of VEGFR-2 in AMDpatients had a significant negative correlation with foveal retinal thickness (r=-0.226, P=0.025) and a significant positive correlation with subfoveal choroidal thickness (r=0.2, P=0.048). CONCLUSION: The current study demonstrated that the decreased serum VEGFR-2 level may be considered in the development of AMD. Adropin does not seem to play a role in the pathogenesis of AMD.
Authors: K Ganesh Kumar; James L Trevaskis; Daniel D Lam; Gregory M Sutton; Robert A Koza; Vladimir N Chouljenko; Konstantin G Kousoulas; Pamela M Rogers; Robert A Kesterson; Marie Thearle; Anthony W Ferrante; Randall L Mynatt; Thomas P Burris; Jesse Z Dong; Heather A Halem; Michael D Culler; Lora K Heisler; Jacqueline M Stephens; Andrew A Butler Journal: Cell Metab Date: 2008-12 Impact factor: 27.287
Authors: Kazuaki Nishijima; Yin-Shan Ng; Lichun Zhong; John Bradley; William Schubert; Nobuo Jo; Jo Akita; Steven J Samuelsson; Gregory S Robinson; Anthony P Adamis; David T Shima Journal: Am J Pathol Date: 2007-07 Impact factor: 4.307
Authors: David Gozal; Leila Kheirandish-Gozal; Rakesh Bhattacharjee; Helena Molero-Ramirez; Hui-Leng Tan; Hari P R Bandla Journal: J Pediatr Date: 2013-06-28 Impact factor: 4.406
Authors: Areekulangara Neethu; Kuppuswami Jayashree; Gandhipuram Periyasamy Senthilkumar; K Ramesh Babu; Mehalingam Vadivelan Journal: J Family Med Prim Care Date: 2020-09-30